Keyphrases
Phase I Study
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Relapsed or Refractory Acute Myeloid Leukemia
100%
Azacitidine
100%
Donor Lymphocyte Infusion
100%
Graft-versus-host Disease (GvHD)
33%
Dose Level
33%
Complete Remission
33%
Treatment Group
11%
Phase 1 Study
11%
Immunosuppression
11%
Increased Incidence
11%
Dose Escalation
11%
Leukemia
11%
Treatment Toxicity
11%
Hematologic
11%
Host Disease
11%
AML Relapse
11%
3 + 3 Design
11%
Regulatory T Cell(Treg)
11%
Relapsed AML
11%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Allogeneic Stem Cell Transplantation
100%
Azacitidine
100%
Donor Lymphocyte Infusion
100%
Graft Versus Host Reaction
33%
Acute Myelogenous Leukemia
22%
Stem Cell Transplant
22%
Immunosuppressive Treatment
11%
Leukemia
11%
Regulatory T Cell
11%
Host
11%
Treatment Group
11%
Immunology and Microbiology
Myeloid
100%
Allogeneic Stem Cell Transplantation
100%
Lymphocyte
100%
Graft-Versus-Host Disease
33%
Regulatory T Cell
22%
Stem Cell Transplant
22%
Immunosuppression
11%
Host
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Azacitidine
100%
Remission
42%
Graft Versus Host Reaction
42%
Leukemia
14%
Host
14%
Treatment Group
14%